Faron Pharmaceuticals (UK) Performance
| FARN Stock | 170.00 2.50 1.49% |
The firm shows a Beta (market volatility) of 0.81, which means possible diversification benefits within a given portfolio. As returns on the market increase, Faron Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Faron Pharmaceuticals is expected to be smaller as well. At this point, Faron Pharmaceuticals has a negative expected return of -0.37%. Please make sure to confirm Faron Pharmaceuticals' potential upside, kurtosis, and the relationship between the value at risk and skewness , to decide if Faron Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Faron Pharmaceuticals Oy has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 5000:4999 | Last Split Date 2019-08-07 |
| Begin Period Cash Flow | 7 M |
Faron |
Faron Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 22,700 in Faron Pharmaceuticals Oy on September 16, 2024 and sell it today you would lose (5,700) from holding Faron Pharmaceuticals Oy or give up 25.11% of portfolio value over 90 days. Faron Pharmaceuticals Oy is generating negative expected returns and assumes 3.6671% volatility on return distribution over the 90 days horizon. Simply put, 32% of stocks are less volatile than Faron, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Faron Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Faron Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Faron Pharmaceuticals Oy, and traders can use it to determine the average amount a Faron Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.101
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FARN |
Estimated Market Risk
| 3.67 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Faron Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Faron Pharmaceuticals by adding Faron Pharmaceuticals to a well-diversified portfolio.
Faron Pharmaceuticals Fundamentals Growth
Faron Stock prices reflect investors' perceptions of the future prospects and financial health of Faron Pharmaceuticals, and Faron Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Faron Stock performance.
| Return On Equity | -39.61 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | 163.6 M | ||||
| Shares Outstanding | 104.62 M | ||||
| Price To Book | 156.09 X | ||||
| Price To Sales | 16.21 X | ||||
| Gross Profit | 803 K | ||||
| EBITDA | (28.37 M) | ||||
| Net Income | (30.94 M) | ||||
| Total Debt | 13.11 M | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (23.81 M) | ||||
| Earnings Per Share | (0.31) X | ||||
| Total Asset | 10.22 M | ||||
| Retained Earnings | (172.21 M) | ||||
About Faron Pharmaceuticals Performance
Assessing Faron Pharmaceuticals' fundamental ratios provides investors with valuable insights into Faron Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Faron Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Faron Pharmaceuticals is entity of United Kingdom. It is traded as Stock on LSE exchange.Things to note about Faron Pharmaceuticals performance evaluation
Checking the ongoing alerts about Faron Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Faron Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Faron Pharmaceuticals generated a negative expected return over the last 90 days | |
| Faron Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (30.94 M) with profit before overhead, payroll, taxes, and interest of 803 K. | |
| Faron Pharmaceuticals generates negative cash flow from operations | |
| About 32.0% of the company shares are held by company insiders |
- Analyzing Faron Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Faron Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Faron Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Faron Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Faron Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Faron Pharmaceuticals' stock. These opinions can provide insight into Faron Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Faron Stock Analysis
When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.